Siga este link para ver outros tipos de publicações sobre o tema: Chronic inflammatory rheumatisms.
Artigos de revistas sobre o tema "Chronic inflammatory rheumatisms"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Chronic inflammatory rheumatisms".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
1
Makita, Chantal, Norbert N’Soundhat, Charles Ngabou e Honoré Ntsiba. "Ocular Reactions during Chronic Inflammatory Rheumatisms". Ophthalmology Research: An International Journal 8, n.º 2 (6 de fevereiro de 2018): 1–5. http://dx.doi.org/10.9734/or/2018/39234.
Texto completo da fonte
2
Esseghir, S., L. Souabni, K. Ben Abdelghani, K. Salma, C. Salma, S. Belhadj, L. Ahmed e Z. Leith. "AB1087 Tuberculosis infections and chronic inflammatory rheumatisms:". Annals of the Rheumatic Diseases 71, Suppl 3 (junho de 2013): 700.7–700. http://dx.doi.org/10.1136/annrheumdis-2012-eular.1086.
Texto completo da fonte
3
Hamdi, O., M. Sellami, S. Miladi, A. Fazaa, L. Souabni, K. Ouenniche, S. Kassab, S. Chekili, K. Ben Abdelghani e A. Laatar. "AB0886-HPR ASSESSMENT OF SEASONAL VARIATIONS ON CHRONIC INFLAMMATORY RHEUMATISMS ACTIVITY". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de maio de 2021): 1466.2–1467. http://dx.doi.org/10.1136/annrheumdis-2021-eular.412.
Texto completo da fonteResumo:
Background:Although rheumatoid arthritis (RA) and spondyloarthritis (SA) activities have been described to vary under the influence of several factors, little is known about the influence of seasonality on the activity of chronic inflammatory rheumatisms.Objectives:To assess the influence of seasonality on the activity of chronic inflammatory rheumatisms.Methods:We conducted a cross-sectional study involving patients with RA (2010 ACR/EULAR criteria) and SA (2009 ASAS criteria). Chronic inflammatory rheumatisms activity was assessed during the summer (June-September) and winter (December-February) using clinical parameters including the Patient’s Global Assessment of disease activity (PGA), 10-cm Visual Analog Scale (VAS) pain score, morning stiffness, nocturnal awakenings, and joint count for RA (tender joint count (TJC) and swollen joint count (SJC)); biological parameters including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); disease activity scores including the SDAI, CDAI and DAS28for RA, BASDAI and ASDASCRP for SA. An analysis of variance (ANOVA) was used to assess the statistical relationship between seasonality and rheumatisms activities.Results:We enrolled 175 patients (100 RA and 75 SA) with a sex ratio of 0.5 and a mean age of 57.75 ± 10.53 years [23-83]. The mean chronic inflammatory rheumatisms duration was 12.38 ± 4.6 years. RA was erosive in 91% of cases. Rheumatoid factor and anti-citrullinated peptides antibodies were positive respectively in 84% and 85% of cases. Seventy-five percent of RA patients were on corticosteroids with a mean dose of 10.14 mg/day of prednisone equivalent and 79% of SA patients were on non-steroidal anti-inflammatory drugs. Eighty percent of our patients were treated with conventional synthetic DMARD and 44% with biological DMARD. Small joints were more affected than large joints regardless of the season in RA patients (p=0.05). The following parameters were higher in winter than in summer in RA patients: mean PGA 4.73 vs 4.64 (p=0.01); mean morning stiffness 1.6 vs 1.1 (p=0.01); mean SJC 8.7 vs 7.5 (p=0.01); mean DAS28 ESR 4.56 vs 3.99 (p= 0.05); mean DAS28 CRP 4.6 vs 3.41 (p= 0.05), mean SDAI 21.8 vs 19.5 (p= 0.05); mean CDAI 20.5 vs 18.75 (p= 0.01) and mean ESR 45.6mm/h vs 38.2 mm/h (p=0.01). As for SA, the following parameters were higher in winter than in summer: mean morning stiffness 2 vs 1.4 (p= 0.01); mean ASDASCRP 3.9 vs 3.1 (p= 0.01) and mean BASDAI 6.2 vs 4.9 (p= 0.05). However, we found no statistically significant correlation between seasonal changes and VAS pain score, nocturnal awakenings, TJC, and CRP.Conclusion:Chronic inflammatory rheumatisms activity was higher in winter. Health care professionals should take seasonal changes into account in order to improve therapeutic care.Disclosure of Interests:None declared
4
Hamdi, O., S. Jemmali, S. Boussaid, S. Rahmouni, S. Rekik, H. Sahli e M. Elleuch. "POS1515-HPR CONJUGAL RELATIONSHIPS IN MARRIED PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISMS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 1102.2–1103. http://dx.doi.org/10.1136/annrheumdis-2022-eular.428.
Texto completo da fonteResumo:
BackgroundThe consequences of chronic inflammatory rheumatisms (CIR) on the sexuality and the relationships between the subject and his/her partner are still underestimated and insufficiently studied.ObjectivesThe aim of this study was to investigate the impact of CIR on conjugal relationships.MethodsWe conducted a cross-sectional study involving patients with rheumatoid arthritis (RA) (2010 ACR/EULAR criteria) and spondyloarthritis (SpA) (2009 ASAS criteria). All the patients included in the study were married. We collected demographic data, and participants were asked to complete a questionnaire on their conjugal relationships.ResultsWe enrolled 75 patients (40 RA and 35 SpA) with a sex ratio of 0.4 and a mean age of 55.35 ± 9.81 years [22-85]. The mean chronic CIR duration was 11.85 ± 3.4 years. The mean duration of marriage was 9.5 ± 2.6 years. The mean age at marriage was 27 ± 6.41 years [19-33]. The mean number of off-springs was 4. Forty-nine percent of patients and 22.3% of the partners had a profession, respectively. Forty one percent of the partners had a chronic disease: diabetes (n=12), hypertension (n=10), dyslipidemia (n=7), CIR (n=7), coronary disease (n=3), and other conditions (n=5). A psychiatric illness was noted in 22.6% of cases: depression (n=9), anxiety (n=6), and bipolar disorder (n=2). Sixty-four percent of patients consider their spouses sympathetic to their illness. Eighty-nine percent of participants have noticed a change in their life as a couple before and after the CIR onset. According to 64% of participants, the CIR had a negative impact on their married lives. The spouses’ emotional reactions to the disease were as follows: indifference (30.6%), denial (29.3%), anger (26.6%), and fear (13.6%). Patients reported being accompanied by their spouses to their medical appointments in 36% of cases, and 40% of them were asked questions by their spouses about their disease and treatment. The CIR has resulted in the termination of the marriage in 2.6% of cases.ConclusionPatients suffering from chronic diseases such as CIR are more frequently exposed to difficulties in their conjugal relationships. The disease has thus important consequences on the subject’s quality of life, emotional and interpersonal state. A better compliance with the chronic disease and its treatment may improve the couples’ relationships.Disclosure of InterestsNone declared
5
Tubery, A., P. Fesler, G. Du Cailar, J. Morel, J. Bousquet, B. Combe e C. Daien. "Interest of a systematic screening of comorbidities in chronic inflammatory rheumatisms". Annals of Physical and Rehabilitation Medicine 58 (setembro de 2015): e120. http://dx.doi.org/10.1016/j.rehab.2015.07.289.
Texto completo da fonte
6
Arabi, H., H. Tebaa, A. Mougui e I. El Bouchti. "AB0320 SACROILIITIS AND ACPA POSITIVE: IS THIS AN ASSOCIATION OF RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS? ABOUT 16 CASES". Annals of the Rheumatic Diseases 82, Suppl 1 (30 de maio de 2023): 1343.3–1344. http://dx.doi.org/10.1136/annrheumdis-2023-eular.6488.
Texto completo da fonteResumo:
BackgroundRheumatoid arthritis (RA) and spondyloarthritis (SpA) in particular psoriatic arthritis (RP) are two distinct inflammatory rheumatisms having in common destructive peripheral involvement.ObjectivesWe report a series of chronic inflammatory rheumatism with features of RA and SpA.MethodsDescriptive retrospective study including patients with chronic inflammatory rheumatism, collected in the rheumatology department over a period of 10 years (2009-2019).Results16 patients were included. The average age was 45.94 ± 12.10 years [28-71], with a female predominance of 87.5%. The mean age at onset of symptoms was 34.69 ± 12.71 years [14-57]. The disease duration was 11.25 ± 10.44 years. History was dominated by hepatic steatosis in 25%, diabetes in 18.8%, hypertension and smoking in 12.5%. A history of familial rheumatism and cutaneous psoriasis was found in only one patient. The revealing symptomatology was dominated by chronic polyarthritis in 75%, polyarthralgia in 18.8% and mono-arthritis in one case. Deformities were described in 43.8%. On the immunological assessment, the mean ACPA was 191.25 ± 155.68 [36-500]. Rheumatoid factor and Anti-nuclear antibodies were positive in 50% and 37.5% respectively. HLA B27 was done in 2 patients, 1 of whom was positive. Sjögren’s syndrome was present in 37.5% of patients. A biological inflammatory syndrome was found in the majority of patients with an average ESR and CRP of 37.38 and 20.41 respectively. Radiographic sacroiliitis was noted in 56.3%, and the rest were non-radiographic. Syndesmophytes were noted in 3 patients (18.8%). Coxitis was present in 12.6%. Structural damage in 81.3% made of erosions, geodes and pinching with reconstruction images in 4 patients.Patients were treated with corticosteroid therapy in 87.5%, methotrexate in 62.5%, sulfasalazine in 43.8%, and biotherapy in 25% of cases with anti-TNF alpha type.ConclusionThese associations pose difficulties in diagnosis and management. A more in-depth study of these patients can help with an accurate diagnosis and therefore with optimal management.REFERENCES:NIL.Acknowledgements:NIL.Disclosure of InterestsNone Declared.
7
Hamdi, O., S. Jemmali, W. Kammoun, S. Boussaid, S. Rahmouni, S. Rekik, H. Sahli e M. Elleuch. "POS1516-HPR CHRONIC INFLAMMATORY RHEUMATISMS: DOES PERIODIC FASTING REDUCE THE DISEASE ACTIVITY?" Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 1103.1–1103. http://dx.doi.org/10.1136/annrheumdis-2022-eular.429.
Texto completo da fonteResumo:
BackgroundMany experimental studies have emphasized the role of periodic fasting in the adaptive responses that reduce inflammation.ObjectivesOur purpose was to assess the impact of periodic fasting on the activity of chronic inflammatory rheumatisms (CIR).MethodsWe conducted a cross-sectional study involving patients with rheumatoid arthritis (RA) (2010 ACR/EULAR criteria) and spondyloarthritis (SpA) (2009 ASAS criteria). CIR activity was assessed during the period of Ramadan (periodic fasting) and three months following Ramadan using clinical parameters including the Patient’s Global Assessment of disease activity (PGA), 10-cm Visual Analog Scale (VAS) pain score, morning stiffness, nocturnal awakenings, and joint count for RA (tender joint count (TJC) and swollen joint count (SJC)); biological parameters including C-reactive protein (CRP); disease activity scores including the SDAI, CDAI and DAS28 CRP for RA, BASDAI and ASDASCRP for SpA. An analysis of variance (ANOVA) was used to assess the statistical relationship between fasting and CIR activity.ResultsWe enrolled 75 patients (40 RA and 35 SpA) with a sex ratio of 0.4 and a mean age of 55.35 ± 9.81 years [22-85]. The mean chronic CIR duration was 11.85 ± 3.4 years. RA was erosive in 92% of cases. Rheumatoid factor and anti-citrullinated peptides antibodies were positive respectively in 82% and 84% of cases. Seventy-five percent of RA patients were on corticosteroids with a mean dose of 10.20 mg/day of prednisone equivalent, and 81% of SpA patients were on non-steroidal anti-inflammatory drugs. Eighty-three percent of our patients were treated with conventional synthetic DMARD, and 40% with biological DMARD. The following parameters were lower in the month of Ramadan compared to the period following Ramadan in RA patients: mean PGA 4.3 vs 4.6 (p=0.01); mean morning stiffness 1.1 vs 1.5 (p=0.01); mean SJC 4.7 vs 8.5 (p=0.01); mean DAS28 CRP 3.56 vs 4.25 (p= 0.05); mean CDAI 17.5 vs 20.35 (p= 0.01), and mean SDAI 13.87 vs 18.44 (p=0.01). As for SpA, the following parameters were lower in the month of Ramadan compared to the period following Ramadan: mean morning stiffness 1.3 vs 2.1 (p= 0.01); mean ASDASCRP 2.9 vs 3.3 (p= 0.01), and mean BASDAI 3.6 vs 4.9 (p= 0.05). However, we found no statistically significant correlation between periodic fasting and VAS pain score, nocturnal awakenings, TJC, and CRP.ConclusionOur study concluded that periodic fasting was associated to a lower CIR activity. The incorporation of periodic fasting may promote optimal health and reduce the activity of some chronic inflammatory diseases.Disclosure of InterestsNone declared
8
Daien, C. I., A. Tubery, P. Fesler, G. Du Cailar, J. Morel, J. Bousquet e B. Combe. "SAT0107 Interest of a Systematic Screening of Comorbidities in Chronic Inflammatory Rheumatisms". Annals of the Rheumatic Diseases 74, Suppl 2 (junho de 2015): 688.3–689. http://dx.doi.org/10.1136/annrheumdis-2015-eular.4722.
Texto completo da fonte
9
S, Bouomrani. "Acute polyarthritis revealing celiac disease of the elderly". General Medicine and Clinical Practice 1, n.º 1 (3 de setembro de 2018): 01–03. http://dx.doi.org/10.31579/2639-4162/004.
Texto completo da fonteResumo:
Introduction: Celiac disease (CD) is an autoimmune disease that typically occurs in childhood and young age. Late-onset forms (after 60 years) are rare and often underestimated in current medical practice, as is joint damage during this disease. We report an original case of CD in an elderly patient revealed by acute polyarthritis. Observation: A 62-year-old patient with no significant pathological history was explored for acute polyarthritis of both large and small joints. The physical examination noted synovitis of the hands and wrists without articular deformities, and a marked mucocutaneous pallor. The biology revealed a microcytic anemia at 8 g/dl with stigmas of malabsorption (low cholesterol and hypocalcemia). No inflammatory syndrome was noted. Joint X-rays were without abnormalities. Immunological tests for chronic inflammatory rheumatisms were negative. Gastroduodenal fibroscopy was performed and histological examination of duodenal biopsies showed diffuse villous atrophy with marked inflammatory infiltrate. Anti- endomysium and anti-transglutaminase antibodies were positive confirming the diagnosis of CD. Under gluten-free diet, the evolution was favorable with totally disappearance of articular signs. Conclusion: Joint manifestations during CD are rare. The revealing forms are exceptional and can make a differential diagnosis with chronic inflammatory rheumatism, in particular that associations with CD was described. CD deserves to be evoked in front of any unexplained arthritis of the elderly, even without any specific digestive symptomatology of this disease.
10
Dobi, Anthony, Philippe Gasque, Pascale Guiraud e Jimmy Selambarom. "Irinotecan (CPT-11) Canonical Anti-Cancer Drug Can also Modulate Antiviral and Pro-Inflammatory Responses of Primary Human Synovial Fibroblasts". Cells 10, n.º 6 (8 de junho de 2021): 1431. http://dx.doi.org/10.3390/cells10061431.
Texto completo da fonteResumo:
Alphaviruses are a group of arboviruses that generate chronic inflammatory rheumatisms in humans. Currently, no approved vaccines or antiviral therapies are available to prevent or treat alphavirus-induced diseases. The aim of this study was to evaluate the repositioning of the anti-cancer molecule irinotecan as a potential modulator of the antiviral and inflammatory responses of primary human synovial fibroblasts (HSF), the main stromal cells of the joint synovium. HSF were exposed to O’nyong-nyong virus (ONNV) and polyinosinic-polycytidylic acid (PIC) to mimic, respectively, acute and chronic infectious settings. The cytokine IL-1β was used as a major pro-inflammatory cytokine to stimulate HSF. Quantitative RT-PCR analysis revealed that irinotecan at 15 µM was able to amplify the antiviral response (i.e., interferon-stimulated gene expression) of HSF exposed to PIC and reduce the expression of pro-inflammatory genes (CXCL8, IL-6 and COX-2) upon IL-1β treatment. These results were associated with the regulation of the expression of several genes, including those encoding for STAT1, STAT2, p53 and NF-κB. Irinotecan did not modulate these responses in both untreated cells and cells stimulated with ONNV. This suggests that this drug could be therapeutically useful for the treatment of chronic and severe (rather than acute) arthritis due to viruses.
11
Daien, C., A. Tubery, G. Du Cailar, T. Mura, M. C. Picot, R. Bourret, F. Roubille et al. "FRI0122 Eular 2015 Recommendations for Cardiovascular Risk Could Radically Change Patients Care in Chronic Inflammatory Rheumatisms". Annals of the Rheumatic Diseases 75, Suppl 2 (junho de 2016): 472.2–472. http://dx.doi.org/10.1136/annrheumdis-2016-eular.2967.
Texto completo da fonte
12
Tubery, A., P. Fesler, G. Du Cailar, J. Morel, J. Bousquet, B. Combe e C. Daien. "AB0986 A Systematic Screening of Comorbidities by The Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care". Annals of the Rheumatic Diseases 75, Suppl 2 (junho de 2016): 1238.2–1238. http://dx.doi.org/10.1136/annrheumdis-2016-eular.2758.
Texto completo da fonte
13
Chan, Pui Shan Julia, e Moon Ho Leung. "A Case of Initially Undiagnosed Chikungunya Arthritis Developing into Chronic Phase in a Nonendemic Area". Case Reports in Medicine 2017 (2017): 1–3. http://dx.doi.org/10.1155/2017/2592964.
Texto completo da fonteResumo:
This case report described a 40-year-old lady presented with fever, headache, arthralgia, myalgia, and impaired liver function after returning from the Philippines. Chikungunya virus (CHIKV) and dengue serology were negative. Eight weeks after initial presentation, she experienced inflammatory polyarthritis mimic rheumatoid arthritis. This time CHIKV-IgM was detected, together with a >4-fold rise of CHIKV-polyvalent-antibody titre. The first CHIKV-IgM negative sample was reexamined and was CHIKV-PCR positive. CHIKV infection was confirmed and diagnosis of CHIKV-related arthritis was made. A quarter of CHIKV infected individuals develop post-CHIKV rheumatisms that affect quality of life and may need treatment with Disease Modifying Antirheumatic Drugs. This case highlights the importance of considering CHIKV infection in patients present with symmetrical polyarthritis particularly after travel to endemic regions. Testing of both CHIKV acute and convalescent-phase serum for CHIKV antibodies and PCR is recommended in suspicious case.
14
Nhiri, R., S. A. Maqdouf e N. Elouafi. "CARDIOTOXICITY: AN UNUSUAL CASE OF METHOTREXATE OVERDOSE". International Journal of Advanced Research 9, n.º 01 (31 de janeiro de 2021): 928–30. http://dx.doi.org/10.21474/ijar01/12372.
Texto completo da fonteResumo:
The methotrexate (MTX) is an antimetabolite, whose dosages vary according to indication. It is used in the treatment of tumoral pathologies, as acute lymphoblastic leukaemias and, in rheumatology, in the rheumatoid polyarthritis (RP) and other chronic inflammatory rheumatisms The methotrexate belongs to the group of antifolates: it inhibits purine and pyrimidine synthesis, which accounts for its efficacy in the therapy of cancer as well as for some of its toxicities. Relative or absolute overdoses in low-dose methotrexate treatments for non-oncological diseases are regularly reported, either in isolated cases or in small series. The bone marrow toxicity with thrombocytopenia and leuconeutropenia is most often the first sign of general involvement. The cardiotoxicity of methotrexate is very rare, in this article we report the observation of pancytopenia associated with cardiotoxicity in a woman treated for RA, for whom the etiological investigation revealed inadvertent methotrexate intoxication by mistake of dosage.
15
Bedoui, Yosra, Claude Giry, Marie-Christine Jaffar-Bandjee, Jimmy Selambarom, Pascale Guiraud e Philippe Gasque. "Immunomodulatory drug methotrexate used to treat patients with chronic inflammatory rheumatisms post-chikungunya does not impair the synovial antiviral and bone repair responses". PLOS Neglected Tropical Diseases 12, n.º 8 (3 de agosto de 2018): e0006634. http://dx.doi.org/10.1371/journal.pntd.0006634.
Texto completo da fonte
16
Farhat, M. M., M. Horn, G. Vaiva, E. Drumez, R. Seror, V. Gaud-Listrat, N. Costedoat-Chalumeau et al. "AB1120 PSYCHOLOGICAL ASSESSMENT IN PATIENTS WITH CHRONIC RHEUMATIC, SYSTEMIC AUTOIMMUNE, OR AUTOINFLAMMATORY DISEASES PRESENTED WITH COVID-19: THE MentCOVRMD STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 1677.1–1677. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2590.
Texto completo da fonteResumo:
BackgroundThe COVID-19 pandemic has raised concerns about its psychological effects. Sleep disturbances, anxiety and/or depressive symptoms, post-traumatic stress symptoms have been reported in general population. Patients with chronic rheumatism, systemic autoimmune disease or auto-inflammatory disease, due to immunosuppression, are at risk of severe forms of infection. Currently, there is little information on psychological impact of the pandemic on the mental health of these more vulnerable patients.ObjectivesTo compare psychological assessment between patients with chronic rheumatic, autoimmune and/or autoinflammatory diseases who presented with COVID-19 infection between March and September 2020, first wave of French pandemic, and patients with same diseases who did not presented with infection to date.MethodsThe MentCOVRMD study was a multicenter descriptive study. Cases were patients with chronic rheumatic, autoimmune and/or autoinflammatory diseases from the French RMD cohort who presented COVID-19 infection between March and September 2020. Controls were patients with same diseases who did not develop infection. The study is registered in Clinical Trials under number 2020-A02058-31.For participants, following criteria were collected: demographics (age, gender, smoking status); psychological assessment questionnaires: Insomnia Severity Index (ISI); Post-traumatic stress disorder (PTSD) checklist; Patient Health Questionnaire (PHQ9) Depression; Generalized Anxiety Disorder (GAD7) Anxiety; Patient Health Questionnaire-15 (PHQ-15) and Somatic Symptom Disorder (SSD)-12.ResultsBetween February and December 2021, 60 cases (46 (76.7%) women), median age 52.0 (39.0; 63.0) were included, of which 15 (25%) had been hospitalized during infection, and 169 controls (148 (87.6%) women), median age of 52.0 (38.0; 63.0). There were more smokers in the group of cases 12 (20%) than controls 14 (9.1%) (p=0.028) as well as more cases on ARA2 treatment (8 (13.3%)) than controls (7 (4.5%)) (p=0.035) with no statistically significant difference in others comorbidities or treatments.There was no statistically difference concerning the ISI scores between cases (11.83 ± 7.31) of which 60% had sleep disorders and controls (11.64 ± 6.82) of which 70.4% had sleep disorders. There was no statistically significant difference in PTSD scores of 15.5 (5.0 to 28.0) for cases and 18.0 (8.0 to 35.0) for controls, of which respectively 12 (20%) had values indicating possible PTSD for cases and 50 (29.6%) for controls. There was no statistically significant difference in PHQ-9 scores (5.5 (1.5 to 11.0)) of which 50% had depressive symptoms and controls (6.0 (2.0 to 11.0)) of which 54.5% had symptoms. There was no statistically significant difference in GAD-7 scores (3.5 (0.0 to 8.0)) of which 40% had anxiety symptoms and controls (4.0 (0.0 to 8.0)) of which 43.2% had symptoms. There was no statistically significant difference in PHQ-15 scores (11.4 ± 6.7), 85% of whom reported presence of symptoms, and controls (10.9 ± 6.2), 82.3% of whom reported symptoms. There was no statistically significant difference in SSD scores between cases (17.7 ± 10.9) and controls (18.4 ± 10.9).There was a statistically significant difference in reported VAS scores of pain related to inflammatory rheumatism in cases with a median of 4.5 (3.0 to 6. 0) compared to controls with a median of 4.0 (1.0 to 6.0) (p=0.011).There was no statistically significant difference in any of the psychological assessment scores between the inpatient and outpatient COVID cases.ConclusionThere was no statistically significant difference between COVID cases and controls in the evaluation of these psychological parameters. Prevalence of all these variables were high in the whole study population, testifying to the need to manage these psychological aspects for patients with chronic rheumatisms, autoimmune and/or autoinflammatory diseases.Disclosure of InterestsNone declared
17
El Ouali, Z., A. Elkebir, K. Nassar, M. Karkouri e S. Janani. "AB0794 CONTRIBUTION OF LABIAL SALIVARY GLAND BIOPSY: EXPERIENCE OF THE DEPARTMENT OF RHEUMATOLOGY OF THE UNIVERSITY HOSPITAL OF IBN ROCHD (ABOUT 57 CASES)". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de maio de 2021): 1422.1–1422. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2755.
Texto completo da fonteResumo:
Background:Labial salivary gland biopsy (LSGB) is a histological examination indicated for the diagnostic workup of systemic diseases such as Sjogren’s syndrome, amyloidosis, or sarcoidosis.Objectives:To study the contribution of LSGB to the diagnosis of Sjogren’s syndrome, amyloidosis, and sarcoidosis.Methods:We conducted a retrospective study of LSGB histopathological reports and clinical data of patient medical records collected in the Department of Rheumatology of the University Hospital of Ibn Rochd, Casablanca, between January 2019 and June 2020. Histology assessed Chisholm and Masson’s sialadenitis score, looked for amyloidosis, and sarcoidotic granulomas.Results:A total of 57 LSGBs were performed, of which 2 were excluded from our study because of lack of clinical data. The sex-ratio M/F was 0.1, and the median age was 53 (22 – 85). The indications were subjective eyes and mouth dryness in 40% of cases, the search for sarcoidosis and amyloidosis in 23.6% of cases, the assessment of a dryness syndrome in the context of chronic inflammatory rheumatism in 18.2% of cases, isolated dryness of the mouth in 14.5% of cases, and the search for amyloidosis in the context of a known primary Sjögren syndrome in 3.6% of cases. The stages of Chisholm and Masson for sialadenitis found were: stage I at 56.6%, stage II at 24.5%, stage III at 11.3%, and stage IV at 7.5%. Among the LSGBs performed for dryness syndrome, stages III and IV were found in 18.2% of cases among subjective eyes and mouth dryness, in 12.5% of cases among isolated mouth dryness, and in 20% of cases among chronic inflammatory rheumatisms. Three cases of AA amyloidosis (5.5%) were diagnosed. No sarcoidosis granulomas were found.Conclusion:LSGB is a simple and frequent investigation. The Chisholm stage most often found in our series was stage I, followed by stages II, III, and IV respectively. This is consistent with the results of the study of Baeteman et al (1). In addition, amyloidosis was only found in our series in 5.5% of cases, also matching with the results of Baeteman et al. (4.2%). Their study showed that LSGB has a great diagnostic interest in these two pathologies, with a sensitivity of 52-75% and a specificity of 90-100% for Sjogren’s syndrome, and a sensitivity of 48-80% and a specificity of 93-100% for amyloidosis (2). LSGB remains a simple investigation test, contributing to the diagnosis of Sjogren’s syndrome, amyloidosis, and sarcoidosis.References:[1]Baeteman C, Guyot L, Bouvenot J, Chossegros C, Cheynet F, Loudot C, et al. Faut-il encore effectuer des biopsies des glandes salivaires accessoires? Revue de Stomatologie et de Chirurgie Maxillo-faciale. 2008 Jun;109(3):143–7.[2]Scardina GA, Spanó G, Carini F, Spicola M, Valenza V, Messina P, et al. Diagnostic evaluation of serial sections of labial salivary gland biopsies in Sjögren’s syndrome. Med Oral Patol Oral Cir Bucal. 1 déc 2007;12(8):E565-568.Disclosure of Interests:None declared
18
Feki, A., I. SELLAMI, M. Baklouti, N. Ketata, Z. Gassara, S. Ben jemaa, M. Ezzeddine et al. "Depression among patients with ankylosing spondylitis in southern Tunisia: Prevalence and associated factors". European Psychiatry 67, S1 (abril de 2024): S528. http://dx.doi.org/10.1192/j.eurpsy.2024.1096.
Texto completo da fonteResumo:
IntroductionAnkylosing spondylitis (AS) is one of the most common inflammatory rheumatisms. It is a chronic, sometimes disabling and it could cause both physical and psychological problems among patients, including depression.ObjectivesWith this in mind, the objective of our work was to study the prevalence of depression among patients with AS and to determine its associated factors.MethodsThis was a retrospective descriptive and analytical study, carried out in 2021 over a period of 5 years in southern Tunisia on patients with a confirmed diagnosis of AS established in accordance with the ASAS diagnostic criteria (Assessment of Spondyloarthritis International Society) or the modified New York criteria for AS. Depression was assessed using the Hospital anxiety and Depression (HAD) score. A HAD score>10 means certain depression.ResultsA total of 62 patients were included in our study. The median age was 39 years with an interquartile range (IQR) = [32-50 years]. There were 35 men (56.5%). Inflammatory back pain was noted among 51 patients (82.3%). Extraarticular manifestations were noted among 14 cases (22.6%) and were mainly ocular (11 cases; 78.4%). The diagnosis was confirmed by ASAS criteria in 55 cases (88.7%). AS was treated symptomatically in 58 cases (93.5%), specifically by basic treatment among 17 patients (27.4%) and by additional physical rehabilitation among 15 patients (24.2%). Depression was certain among 30 patients, giving a global prevalence of 48.4%. The factors statistically associated with this disease among patients with AS were having a low level of education (illiterate or primary) (Odds Ratio (OR) = 2.87; p = 0.044), being clinically suffering from severe fatigue (OR= 7.14; p<0.001), have a poor quality of life [Ankylosing spondylitis quality of life questionnaire (Asqol) Score ≥13] (OR=4.52; p=0.007) and have certain anxiety (HAD>10) (OR=19; p<0.001).ConclusionsIn addition to its clinical impact on patients, the psychological impact of AS was considerable in terms of depression. The factors associated with it were individual, clinical, and psychological. Thus, psychological support must be coupled with AS medical management in order to prevent psychological disorders among patients, particularly depression.Disclosure of InterestNone Declared
19
Sacco, Keith A., e Razvan M. Chirila. "Postchikungunya Chronic Inflammatory Rheumatism". Case Reports in Rheumatology 2016 (2016): 1–3. http://dx.doi.org/10.1155/2016/7068901.
Texto completo da fonteResumo:
A 65-year-old male resident of Guatemala presented with a 5-month history of distal symmetric arthritis and generalized fatigue. This was associated with night sweats, chills, and weight loss. Symptoms were refractory to oral prednisone and hydroxychloroquine.
20
Szabo-Kocsis, K., e M. Dare. "SAT0653-HPR COMMUNITY RHEUMATOLOGY SERVICE IN THE UK – WHO BENEFITS THE MOST?" Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 1285.2–1286. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6550.
Texto completo da fonteResumo:
Background:Community rheumatology (CR) in the UK is a new form of rheumatologic service provision established in the last few years and run by few organisations such as Connect Health Ltd.CR is based on the principle of sharing the management of rheumatologic patients between community service and secondary care aiming to reduce the unreasonable referral flow from primary care to secondary care and to share the care of stable inflammatory patients between the services.In the traditional service model patients are referred by General Practitioners (GP) to the secondary care with a wide spectrum of conditions: from fibromyalgia through soft tissues rheumatisms to inflammatory or connective tissue diseases. Many of these patients will be discharged from the specialist service after their first visit with fibromyalgia, osteoarthritis, chronic pain syndrome or MSK diagnoses. The proportion of these patients versus those who have an inflammatory rheumatologic condition or connective tissue disease (CTD) varies significantly and can contribute to oversaturated specialist rheumatologic services with long waiting time where specialists deal with less relevant cases.Objectives:To determine how CR can improve quality of care and decrease the waiting time for appointment in secondary care rheumatology services. To set standards for referral pathways and measured outcomes of effectiveness in patient care.In the UK the regional Clinical Commissioning Groups would accept a maximum waiting time from the referral until patient treatment of up to 18 weeks and specialist services often breach that limit. This long interval may have a significant negative impact for the care of patients with rheumatological condition, reducing patient satisfaction and/or jeopardize patient safety. The solution to the above problem is the creation of CR service.Methods:Extensive search about the available resources within UK NHS system in regards CR service creation and set up. Web search, literature review in relation to CR in the UKResults:From the research different models of CR can be identified and one of these will be presented in details based on the experience of one of the largest organisation running CR services in the UK (Connect Health Ltd). This service is organised within community care set up and can accept patients referred by the primary care physicians with non-inflammatory symptoms (e.g. osteoarthritis, Ehlers - Danlos Syndrome, fibromyalgia) or PMR or gout. The service also can review stable inflammatory patients who are treated with DMARDs and are transferred from the secondary care service by their consultant. This presentation will demonstrate how CR provides safer, faster and more accessible services to the patients assisting the specialist services and allowing them to concentrate on the inflammatory and CTD patients who need faster access to these services than it is possible now. Particularly the presentation will emphasise on:Patient population coverTeam structure, their experience and trainingReferral criteria and IT set up for multidisciplinary connectionTime interval for appointment and patient feedbackImpact on the secondary care rheumatology serviceCases of misdiagnosis and inappropriate referralsCost effectiveness of the CRChallenges in the CR serviceConclusion:The CR service can be a safe addition to the specialist services taking over significant workload and provide new career opportunities for a wide range of Allied Health Professionals (AHP) for the bigger satisfaction of the patients who can access rheumatology service earlier and easier.Disclosure of Interests:None declared
21
Ben Abdelghani, Kaouther, Alia Fazaa, Khaoula Ben Abdelghani, Ahmed Laatar, Adel Khedher e Leith Zakraoui. "Chronic Inflammatory Rheumatism Associated With Takayasu Disease". Annals of Vascular Surgery 27, n.º 3 (abril de 2013): 353.e1–353.e6. http://dx.doi.org/10.1016/j.avsg.2011.11.048.
Texto completo da fonte
22
Buchheit, Jonathan, Antoine Serre, Xavier Bouilloux, Marc Puyraveau, Laurent Jeunet e Patrick Garbuio. "Cementless total knee arthroplasty in chronic inflammatory rheumatism". European Journal of Orthopaedic Surgery & Traumatology 24, n.º 8 (17 de setembro de 2013): 1489–98. http://dx.doi.org/10.1007/s00590-013-1316-9.
Texto completo da fonte
23
Grondin, Karine, Cécile Lalanne, Jean-Marc Sobhy Danial, Claire Jesson, Laetitia Diep, Maxime Aboudiab, Stéphanie Rouanet, Sarah Salomon-Goëb e Vincent Goëb. "Emotional repression in patients with chronic inflammatory rheumatism". Journal of Clinical and Translational Research 10, n.º 2 (28 de março de 2024): 00099. http://dx.doi.org/10.36922/jctr.23.00099.
Texto completo da fonteResumo:
Background: A person’s psychological background may support and direct the inflammatory evolution of a disease toward a specific type of chronic inflammatory rheumatism (CIR). Aim: This study aimed to identify a particular emotional profile of patients with CIR, particularly rheumatoid arthritis (RA) and spondyloarthritis (SpA), based on psychological profile assessments between patients with and without CIR. Emotional repression, that is, a tendency to inhibit the expression of negative feelings and/or unpleasant thoughts, was particularly studied. Methods: This monocentric observational pilot study included patients from the rheumatology department of a university hospital. These patients were systematically assessed for different psychological parameters by an experienced psychiatrist, and their clinical and biological characteristics were collected accordingly. Data analysis was performed using the Chi-squared test or Fisher’s exact test. Results: Fifty-nine patients were assessed: 47 patients with CIR (i.e., 27 with RA and 20 with SpA) (CIR group) and 12 non-CIR patients (i.e., nine with osteoarthritis, one with viral disease, one with osteoporosis, and one with osteomalacia) (control group). Severe emotional repression and early life events were both significantly higher in the CIR group than in the control group (P = 0.02). In contrast, severe psychological and somatic complaints were significantly higher in the control group than in the CIR group (P < 0.01 and P = 0.01, respectively). Conclusion: Our findings suggested that emotional repression from traumatic life events could aggravate the etiology and/or course of CIR. Therefore, appropriate psychological care should have a relevant place within the current therapeutic options for the clinical management of CIR. Relevance for Patients: The management of CIR should include psychological support as learning coping mechanisms can facilitate the recovery of CIR patients.
24
Hamdi, O., M. Sellami, M. Yasmine, A. Fazaa, S. Miladi, L. Souabni, K. Ouenniche et al. "AB0814 PREGNANCY COURSE ASSESSMENT IN PATIENTS WITH RHEUMATIC DISEASES COMPARED TO CONTROLS". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de maio de 2021): 1431.2–1432. http://dx.doi.org/10.1136/annrheumdis-2021-eular.413.
Texto completo da fonteResumo:
Background:Rheumatic diseases such as rheumatoid arthritis (RA) and spondyloarthritis (SA) may occur among women of childbearing age. Adverse events during pregnancy including disease flare, preterm delivery, and neonatal or fetal death have been reported.Objectives:Our aim was to assess the impact of rheumatic diseases on the course of pregnancy.Methods:We conducted a cross-sectional study involving patients with RA (2010 ACR/EULAR criteria) and SA (2009 ASAS criteria) (study group) as well as healthy controls (control group) matched by age and gender. All women included had at least one pregnancy. Data were collected through telephonic interviews. We used the Student t test to compare the study group and the control group.Results:We enrolled 57 patients (30 RA and 27 SA) and 57 controls. The mean age in the study and the control groups were respectively 43.2 ± 8.2 years [26-48] and 37.5 ± 6 years. The mean chronic inflammatory rheumatisms duration was 13.81 ± 6.2 years. A history of primary sterility was found in 3 patients (1 RA and 2 SA) and none in the control group. The mean age during the first pregnancy was significantly higher in the study group (28 ± 6.2 years versus 24 ± 7 years in the control group) (p=0.01). Eight patients (5 RA and 3 SA) had a history of spontaneous miscarriage. A terminated pregnancy was noted in 3 patients (1 RA and 2 SA). Complications during pregnancy in the study group were gestational diabetes (0.3%), premature delivery (0.3), premature rupture of membranes (0.3%), abortion threat (0.3%) and pre-eclampsia (6%). Pregnancy was more associated with complications in the study group (p=0.05). Cesarean section was more used in the study group (28 patients versus 9 in the control group; p= 0.00). The main indications of cesarean section in the study group were macrosomia (11 patients), scar uterus (6 patients), sacroiliitis (4 SA patients), twin pregnancy (2 patients), and undetermined reasons (6 patients). Fetal presentation in the study group was the seat presentation (3%), top presentation (4%), face (2%), and forehead presentation (0.3%) with no significant difference with the control group. Complications of childbirth in the study group were hemorrhage of delivery (10.3%), cord widening (6.6%), perinatal asphyxia (4.9%), and dystocia (1.9%). However, no statistically significant differences were found between the two groups in the prevalence of complications of childbirth. During pregnancy, 5 patients were on salazopyrine, 2 on corticosteroids and, 1 on non-steroidal anti-inflammatories.Conclusion:Our study showed that pregnancies with rheumatic diseases were at increased risk of having maternal complications and adverse neonatal outcomes.Disclosure of Interests:None declared
25
Raihane Bahri, Fadoua Elfarssani, Siham Khayati, Saida Eddyb, Hajar Saffour, Abderrahman Boukhira e Saliha Chellak. "Analytical characteristics of faecal and serum calprotectin or calprotectin assay: What clinical interest?" GSC Advanced Research and Reviews 6, n.º 3 (30 de março de 2021): 156–63. http://dx.doi.org/10.30574/gscarr.2021.6.3.0052.
Texto completo da fonteResumo:
Calprotectin is a calcium binding protein expressed at the inflammatory site by neutrophils and monocytes to activate the innate immune system. Thanks to this unique characteristic, it is a good indicator of local inflammation in chronic inflammatory rheumatism. All of the data highlight the key role that calprotectin plays in the inflammatory process in several inflammatory rheumatism. The value of serum and faecal calprotectin assays has been widely studied in recent years, in particular in rheumatoid arthritis, spondyloarthritis, juvenile idiopathic arthritis and vasculitis associated with ANCA but also for chronic inflammatory bowel disease. calprotectin has been identified as a powerful biomarker that allows the evaluation and monitoring of the activity of disease but also to predict structural evolution or response to treatment. Calprotectin is also a predictive biomarker of risk relapse. In this review, we discuss the value of calprotectin in chronic inflammatory affections as a diagnostic, potency or prognostic biomarker.
26
Rahal, Fadia, Amina Abdessemed, Radia Chetouane, Sabrina Haid, Naoual Khaldoun, Salima Lefkir, Nadjia Brahimi e Aicha Ladjouze-Rezig. "Early rheumatoid arthritis diagnosis". Batna Journal of Medical Sciences (BJMS) 1, n.º 1 (1 de julho de 2014): 12–17. http://dx.doi.org/10.48087/bjmstf.2014.1105.
Texto completo da fonteResumo:
Rheumatoid arthritis is the most frequent chronic inflammatory rheumatism. Its management, especially in the case of early inflammatory rheumatism should be immediate, if possible, during the first six months of the evolution of the disease and should be adapted to the potential evolution of rheumatism because it is a therapeutic emergency. Management was drastically improved by a better knowledge of pathophysiology (role of anti-CCP antibodies established), a new diagnostic approach (new 2010 ACR/EULAR criteria and new international recommendations), and new prognostic and therapeutic approaches (biologics).
27
Verhoeven, F., C. Prati, V. DI Martino, T. Thevenot, D. Wendling e W. V. Delphine. "AB0945 ASSESSMENT OF THE RISK OF LIVER FIBROSIS IN SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB: A SINGLE-CENTER RETROSPECTIVE OBSERVATIONAL STUDY". Annals of the Rheumatic Diseases 82, Suppl 1 (30 de maio de 2023): 1690.2–1690. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3103.
Texto completo da fonteResumo:
BackgroundThe prevalence of non-alcoholic steatopathy (NAFLD) is increasing in chronic inflammatory rheumatisms. NAFLD may favor the development of liver fibrosis, which may lead to cirrhosis and its complications including hepatocellular carcinoma. The process of hepatic fibrogenesis involves inflammatory mechanisms with an overexpression of TNF but also of IL 17. Thus, the use of anti-TNF alpha is associated with a decrease in the incidence of hepatic fibrosis. Anti-IL-17 could also have an effect on fibrogenesis but this has not been studied in spondyloarthritis.ObjectivesThe aim of this study was to assess, non-invasively, the risk of liver fibrosis using the FIB-4 score, in patients treated with anti-IL-17.MethodsA single-center retrospective observational study was performed. We included all consecutive patients followed between 2015 and 2022 for axial spondyloarthritis (axSpA) meeting the ASAS 2009 criteria or psoriatic arthritis (PsA) meeting the CASPAR criteria, treated for at least 12 months with secukinumab, and for whom at least 12 months of biological follow-up was available. For each patient, we collected demographic data, clinical data, associated treatments, and levels of AST, ALT, platelets at initiation of treatment and after 12 months of treatment. We assessed the FIB-4 score (age(years) * ASAT (U/L))/(platelets (109/L)*√ALAT (U/L))at M0, M12, and M24. Fischer’s exact test was used for comparison between categorical variables and Student’s t test for quantitative variables.Results38 patients, (20 PsA, 18 axSpA; 60% women in both groups; mean age 57 years in PsA group and 46 years in axSpA group (p<0.01)) were included. The mean disease duration was 10 ± 4 years in the PsA group and 11 ± 5 years in the axSpA group. 78% of axSpA were HLA B27 positive versus 20% of PsA (p<0.01). There was a trend towards a higher prevalence of NAFLD (30% vs. 5%, p=0.09) and previous methotrexate use was more frequent (100% VS 39%, p<0.01) in PsA. The FIB4 score was higher in the PsA group at baseline (1.30 ± 0.24 VS 0.74 ± 0.05; p=0.04). This difference remained significant after 12 months of treatment (1.34 ± 0.25 vs. 0.79 ± 0.06; p=0.048). At M0, no axSpA patient had a FIB4 > 1.3 vs. 6 in the PsA group. At M12, one axSpA patient had a FIB4>1.3 (and <2.0) vs. 6 in the PsA group (including 4 patients with a FIB4>2.0). At M24, one axSpA patient out of 6 had a FIB4>1.3 (and <2.0) versus 3 in the PsA group out of 13 (including 1 patient with FiB4>2.0 and 1 with FiB4<1.3 at inclusion). The overall change in FiB-4 score at 1 year was not different in the PsA and axSpA groups (-0.62 ± 0.25 vs. -0.59 ± 0.27; p=NS). Finally, PsA patients suffer from NAFLD did not worsen their FiB4 score (2.08 ±1.6 at M0 VS 2.02 ± 1.07 at M12; p=NS).ConclusionIn PsA and axSpA, 1-year treatment with secukinumab is not associated with an increase in FIB-4 even in patients known to have NAFLD. This study requires confirmation in a larger cohort.Figure 1.REFERENCES:NIL.Acknowledgements:NIL.Disclosure of InterestsNone Declared.
28
Fakih, Olivier. "Managing Inflammatory Bowel Disease in Spondyloarthritis". Rheumatology 2, n.º 1 (2023): 7. http://dx.doi.org/10.17925/rmd.2023.2.1.7.
Texto completo da fonteResumo:
Spondyloarthritis is a chronic inflammatory rheumatism associated with a variety of extra-articular manifestations, including chronic inflammatory bowel disease (Crohns disease and ulcerative colitis). Subclinical gastrointestinal manifestations in patients with spondyloarthritis are common, and clinical involvement exists in a number of patients. The pathophysiology remains poorly understood and involves genetic and immunological factors, as well as the gut microbiome. Screening for inflammatory bowel disease in patients with spondyloarthritis is important because its occurence modifies the therapeutic management of these patients.
29
Popkova, T. V., e D. S. Novikova. "ACCORDING TO THE MATERIALS OF THE 2015/2016 NEW EUROPEAN LEAGUE AGAINST RHEUMATISM (EULAR) GUIDELINES FOR REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY ARTHRITIS: GENERAL CHARACTERIZATION AND DISCUSSION PROBLEMS". Rheumatology Science and Practice 56, n.º 3 (15 de julho de 2018): 272–79. http://dx.doi.org/10.14412/1995-4484-2018-272-279.
Texto completo da fonteResumo:
According to the materials of the 2015/2016 new European League Against Rheumatism (EULAR) guidelines for reducing cardiovascular risk in patients with inflammatory arthritis. The authors identify three main principles of prevention of cardiovascular diseases in rheumatoid arthritis and other chronic inflammatory arthritis and provide a general characterization of the guidelines, by reviewing the discussion problems.
30
Idrissi Zaki, F., F. E. Chekkouri, A. Mougui e I. El Bouchti. "POS1181 INFECTIOUS COMPLICATIONS OF BIOLOGIC THERAPY IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISM". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 918.2–919. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2831.
Texto completo da fonteResumo:
BackgroundThe appearance of biological disease-modifying drugs (bDMARDs) has revolutionized the treatment of rheumatic diseases. However, their functions in modulating pro-inflammatory cytokines and acquired immunity largely increase the risk of infections.ObjectivesThe aim of this work is to study the epidemiological, clinical and biological characteristics of infections occurring under biotherapies, and to identify the factors associated with its occurrence.MethodsIt is a retrospective descriptive study including patients with chronic inflammatory rheumatism between 2006 and 2021 and who were placed during their follow-up under a biotherapy. Statistical data analysis was performed using SPSS version 20 software. The bivariate study was performed by Chi-square test.ResultsOf the 106 cases reported, 68 infectious episodes were counted in 46 patients (43.4%) who had at least one infection with biotherapy: 56.5% women and 43.5% men with an average age of 50.9 ± 14.29 years. These included rheumatoid arthritis in 16 patients (34.8%), spondylarthritis in 29 patients (63%) and one case of psoriatic arthritis. All patients were on conventional treatments before switching to biotherapy. The infections occurred under Rituximab in 43.8% of the cases, under Infliximab in 33.3% of the cases, under Etanercept in 25% of the cases (a total of 60.9% of the cases were under anti-Tumor Necrosis Factor) and tocilizumab in 12.5% of cases. The infection was of bacterial origin in 40.7% of cases: 27.3% urinary tract infections, 20.5% bronchial infections, 11.4% skin infections, 6.8% septic arthritis. Fungal infections were found in 33.3% of cases in relation to dermatophyte infections and intertrigo. A viral origin was noted in 25.9% of the cases: 5 cases of labial herpes and only one case on herpes zoster.C-reactive protein was increased in 47.2% of cases with a mean value of 36 ± 29.6 mg /L, the hemogram showed hyperleukocytosis in 50% of cases with neutrophil predominance. The treatment was medical in the majority of cases (94.9%), it was both medical and surgical in one case.The favorable outcome in all patients was marked by a temporary interruption of 3.27 ± 1.84 weeks of biotherapy.In multivariate analysis, an association was found between bacterial infection and both female gender (p=0.033), low socioeconomic level (p=0.033), Methotrexate + bDMARDs intake (p=0.027), corticosteroids + bDMARs intake (p=0.014) and Between fungal infection and bDMARs +corticosteroids intake (p=0.044).ConclusionThe risk of infection is higher in patients with chronic inflammatory rheumatism, especially if they are under biotherapy. It turns out that bacterial and fungal infections are the most common in this study. Patients taking Rituximab or Infliximab are the most affected by these infectious episodes.References[1]Meyer-Olson D, Hoeper K, Schmidt R. Infektionskomplikationen unter Biologika-Therapie bei Patienten mit rheumatoider Arthritis. Z Rheumatol. 2010 Dec;69(10):879-88.[2]Lortholary O, Fernandez-Ruiz M, Baddley JW, et al. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Annals of the Rheumatic Diseases. 2020;79:1532-1543.[3]Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev. 2020 Jun 17;33(3).Disclosure of InterestsNone declared
31
Fayet, Françoise, Malory Rodere, Carine Savel, Bruno Pereira, Martin Soubrier e Marion Couderc. "Education models and acquisition of biotherapies safety skills in chronic inflammatory rheumatism". Education Thérapeutique du Patient - Therapeutic Patient Education 11, n.º 1 (1 de maio de 2019): 10206. http://dx.doi.org/10.1051/tpe/2019004.
Texto completo da fonteResumo:
Introduction: The biotherapies prescribed to chronic inflammatory rheumatism patients carry risks, about which these patients must be informed. Objective: To evaluate which educational model is the best for maintaining optimal safety in terms of biotherapy self-management. Method: This observational retrospective monocentric study involved patients who had received therapeutic education while on biotherapy from 2009 to 2013, categorized in terms of the educational model received (information: M1, individual education: M2, in terms of the educational model received (information: M1, individual education: M2, individual and group education: M3) and given the Biosecure questionnaire (assessing their theoretical and practical understanding of biotherapy) to complete. Results: Overall, 222 patients were included (67% women, mean age: 53.9 years), 106 of whom had received M1, 88 M2, and 28 M3. The highest Biosecure scores were generated by young, female, employed, college-level educated patients, with the most recent diagnoses, and on intravenous biotherapies. The mean Biosecure score was 76.6 (±13.8) (min-max: 11.52–100). On multivariate analysis, the Biosecure total score was highest in the M3 group, compared to M1 (p = 0.02) and M2 (p = 0.04). Conclusion: The combination of individual and group education resulted in higher Biosecure scores than individual education or simply providing information.
32
Poivret, D., D. Lebouc, S. Sfedj, P. Preiss, M. Jabri e C. Raynaud. "AB1129 How to Improve Adhesion to the Treatment for Chronic Inflammatory Rheumatism". Annals of the Rheumatic Diseases 73, Suppl 2 (junho de 2014): 1175.3–1175. http://dx.doi.org/10.1136/annrheumdis-2014-eular.1305.
Texto completo da fonte
33
Zakaria, Z. A., M. K. Hussain, A. S. Mohamad, F. C. Abdullah e M. R. Sulaiman. "Anti-Inflammatory Activity of the Aqueous Extract of Ficus Deltoidea". Biological Research For Nursing 14, n.º 1 (28 de janeiro de 2011): 90–97. http://dx.doi.org/10.1177/1099800410395378.
Texto completo da fonteResumo:
Ficus deltoidea (Family Moraceae) leaves have been used traditionally by the Malays to treat ailments such as wounds, sores, and rheumatism. The aim of the present study was to determine the anti-inflammatory activity of the aqueous extract of F. deltoidea leaf (FDA) using acute and chronic inflammatory models. FDA, in the doses of 30, 100, and 300 mg/kg, was administered intraperitoneally in rats ( n = 6) before the animals were subjected to the carrageenan-induced paw edema test, cotton pellet-induced granuloma test, and formalin test. The first two tests represent acute and chronic models of inflammation, respectively. The first and second phases of the formalin test represent neurogenic pain and inflammatory-mediated pain, respectively; thus, only the second phase was measured in the present study. Results showed that FDA exerted significant ( p < .05) anti-inflammatory activity in all assays, with dose–response effects seen in the paw edema and formalin tests. In conclusion, the leaf of F. deltoidea possesses anti-inflammatory activity against acute and chronic inflammatory responses and against pain-associated inflammatory response. These findings justify the traditional uses of F. deltoidea leaves for treatment of inflammatory-mediated ailments.
34
Gaujoux-Viala, C., C. Traverson, E. Filhol, C. Daien, S. Laurent-Chabalier, B. Combe, C. Lukas, J. Morel e C. Hua. "POS1239 POSITIVE IMPACT OF THE FIRST LOCKDOWN IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISM". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de maio de 2021): 902.2–903. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3203.
Texto completo da fonteResumo:
Background:Since the beginning of 2020, the COVID-19 pandemic has caused a considerable amount of fear, worry and concern in the general population and among certain groups such as the elderly, healthcare providers and people with pre-existing conditions in particular. Our patients suffering from chronic inflammatory rheumatism (CIR), a group of autoimmune pathologies treated by immunosuppressant medication, are particularly concerned. Actions taken – particularly quarantine and its effects on the normal activities, habits or livelihoods of many people – also have a significant impact. There is little information on the impact of the lockdown in patients with CIR with data measured prospectively, in a standardized way, before and during the first lockdown period.Objectives:The objective of this ancillary study was to evaluate the psychological impact of the first lockdown period (anxiety, depression, sleep disorders, catastrophizing...) as well as the evolution of disease activity in patients suffering from CIR.Methods:At two French university hospitals, adult patients with rheumatoid arthritis (RA) according to the ACR-EULAR 2010 criteria, spondyloarthritis (SpA) fulfilling the ASAS 2009 criteria and psoriatic arthritis (PsA) according to the Caspar 2006 criteria were consecutively included in the Catastrophism in Chronic Inflammatory Rheumatism (CRIC) study from September 2019. Sociodemographic data, information on the disease and its treatments were collected as well as questionnaires on disease activity (DAS28, CDAI, BASDAI), function (HAQ), quality of life (SF12, EQ5D), anxiety and depression (HADS, GAD7), insomnia (ISI) and catastrophizing scores (PCS). These data were collected prospectively at baseline, 3, 6 and 12 months.In this ancillary study, data from patients with an assessment before and during lockdown were analyzed. Statistical analyses were descriptive with a paired Student’s T-test.Results:In all, 140 patients (49 RA, 69 SpA and 22 PsA) were evaluated before and during lockdown. The median age was 53.5 [44-63] years and 60.7% were women; 74 patients (53.2%) were professionally active and 102 (72.9%) were living as couples. The majority of patients (92.9 %) had a disease lasting more than 2 years. Concerning treatments, 63 (45%) were treated by bDMARD monotherapy, 40 (28.5%) by bDMARD+ csDMARD, 17 (12.1%) by csDMARD monotherapy and 2 patients by tsDMARD; 90.7% were not taking any corticosteroids and 8.6% were taking ≤5 mg/d; 30% were on NSAIDs.When comparing before and during lockdown, pain, tender joint count, swollen joint count, disease activity (CDAI, BASDAI) and function (HAQ, SF12 physical component) were similar. However, there was a significant improvement in psychological status, anxiety (HADS, GAD7), the mental component of SF12, catastrophizing and overall quality of life (EQ5D) (see Table 1 below).Conclusion:There are very few prospective, standardized data on the impact of lockdown in patients with CIR with an assessment before and during the first lockdown period. In patients with CIR, the first lockdown period had no impact on the activity of the disease and was well experienced psychologically with less anxiety and an improvement in quality of life.Table 1.Outcome (N)140 CIR: 49 RA, 69 SpA, 22 PsABefore lockdownMean (SD)During lockdownMean (SD)Mean change(SD)PPain VAS (138)39.4 (25.3)39.4 (25.0)-0.28 (27.1)NSTJC (57)4.0 (6.8)4.7 (4.4)0.7 (5.9)NSSJC (56)1.0 (2.6)1.6 (1.7)0.5 (2.4)NSCDAI (36)11.7 (1.4)12.3 (7.5)1.2 (8.7)NSBASDAI (84)4.7 (1.9)4.9 (2.0)0.14 (1.4)NSHAQ (135)0.72 (0.57)0.72 (0.53)0.03 (0.33)NSSF12 mental(136)32.7 (8.7)36.2 (8.4)3.46 (8.01)<0.0001GAD-7 (anxiety) (135)7.7 (5.5)5.0 (5.3)-1.73 (0.40)<0.0001HADS anxiety(137)8.5 (3.9)7.8 (3.9)-0.64 (2.91)0.0113EQ5D(139)0.55 (0.31)0.61 (0.29)0.06 (0.24)0.0078PCS (catastrophizing) (137)18.9 (13.3)15.9 (11.1)-3.10 (9.60)0.0003Disclosure of Interests:None declared
35
Chowdhury, Md Arifur Rahman, Md Jahidul Islam, Md Aminul Alam, Nuzhat Nuery, Mohammed Kamruzzaman e Sayma Sadia. "Spectrum of Rheumatic Disease in Physical Medicine and Rehabilitation Department in a Tertiary Level Hospital in Bangladesh". Saudi Journal of Medicine 8, n.º 09 (3 de setembro de 2023): 473–80. http://dx.doi.org/10.36348/sjm.2023.v08i09.002.
Texto completo da fonteResumo:
Background: An umbrella term encompassing diseases that damage the joints and/or connective tissue and cause chronic, frequently intermittent discomfort is rheumatism. Rheumatism is a general term that refers to at least 100 distinct diseases and disorders. Given the dearth of research on this subject, the study's goal was to investigate the range of rheumatic disease among patients presenting as outpatients in the Physical Medicine & Rehabilitation department of a tertiary level hospital. Objective: To evaluate the spectrum of rheumatic disease in a tertiary level hospital in Bangladesh. Materials and Methods: This cross-sectional study was carried out at the Physical Medicine and Rehabilitation department of the DMCH for six months. The study sought to enroll patients who had musculoskeletal problems or systemic symptoms that would indicate rheumatic illness. After meeting the requirements, patients were accepted. Each respondent provided written informed consent, and those who refused to engage in the study or undertake additional research were not included. By conducting a face-to-face interview with the respondents and utilizing a pre-tested semi-structured questionnaire, information about the respondents' socio-demographic characteristics, disease duration, clinical symptoms and signs, and investigations report was gathered. Data analysis was done in SPSS-16. Results: Mean age of respondents was 46.36±12.25 years (male= 50±11.68 years and female= 44.19±12.03 years [age range 21-70 years] with 35.7% male and 64.3% female. Around 54.17% of the cases presented with articular symptoms, 43.23% of the patients had degenerative and 10.94% had inflammatory joint diseases. Among the inflammatory arthritis, (38.09%) rheumatoid arthritis and (30.95%) Ankylosing spondylitis was most common whereas (28.92%) lumbar spondylosis and peripheral (28.31%) osteoarthrosis were predominating among non-inflammatory arthritis. Nonspecific back pain was the commonest (60.12%) of specific disorders included in soft tissue rheumatism, followed by (25.77%) adhesive capsulitis of shoulder. Conclusion: Articular disorders both non-inflammatory & Inflammatory, soft tissue rheumatism, disorder of bone and multi-system disorders; these four types of disorder were encountered in this tertiary care hospital.
36
Aharrane, F. Z., F. Z. Taik, N. Takhrifa, R. Bensaid, M. Fourtassi e F. E. Abourazzak. "AB1828-HPR ASSOCIATION BETWEEN COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AND TRUST IN THE PHYSICIAN IN PATIENTS WITH INFLAMMATORY RHEUMATISM?" Annals of the Rheumatic Diseases 82, Suppl 1 (30 de maio de 2023): 2146.1–2146. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2735.
Texto completo da fonteResumo:
BackgroundGenerally, patients with chronic rheumatic diseases use complementary and alternative medicine (CAM) in addition to their conventional treatments to manage their health. Discussing these treatments with their physician is still rare, which might be directly related to patients’ trust toward them.ObjectivesThe primary objective of this study was to assess the association between patients’ trust in their physician and the use of complementary and alternative medicine. As a secondary objective, to estimate the prevalence of complementary and alternative therapy use among patients with chronic inflammatory rheumatism.MethodsThis is a cross-sectional study, which included patients with established chronic inflammatory rheumatism, followed at the University Hospital Center in Tangier. The questionnaire included demographic and clinical information, use of conventional therapy, complementary and alternative therapy, as well as the interpersonal trust in patient-physician relationships using the Trust in Physician Scale (TPS).ResultsThe study included 189 patients. 57.14% of patients reported using complementary medicine at least once, most patients were women (77.78%), mean age was 46.67±13.25 years with an average course of the disease 11.11±9.23 years. The most frequent used complementary and alternative treatments were cupping therapy (45.90%), massage (40.40%) and the ingestion of a mixture of plants (27%). Mean±SD Trust in Physician Scale was 47.64 ±7.2, and there were no significant differences between CAM users vs. non-users (48.08±6.9 vs. 47.04±7,4; p=0,35).ConclusionMore than half of patients with inflammatory rheumatism reported the use of complementary and alternative medicine. However, the association between their use and trust in the physician assessed with TPS was not established.REFERENCES:NIL.Acknowledgements:NIL.Disclosure of InterestsNone Declared.
37
Nagovitsina, A. I., Z. S. Kornyaeva, Z. Ya Soboleva, F. N. Ivshin e V. N. Borozdina. "Peculiarities of the clinical course and complex therapy of peritonitis after cesarean section". Kazan medical journal 67, n.º 6 (15 de novembro de 1986): 450–51. http://dx.doi.org/10.17816/kazmj70916.
Texto completo da fonteResumo:
We observed 23 women who developed peritonitis after cesarean section. The average age of the patients was 28.9 years. There were 7 first-pregnant women and 16 second-pregnant women. The anamnesis revealed the presence of endogenous foci of infection in all the patients. Thus, flu, sore throat, acute respiratory infections were diagnosed in 20 women, pneumonia in 3; chronic pyelonephritis in 5, inflammatory uterine appendages in 6, rheumatism with mitral valve insufficiency in 1, Botkin disease in 1. Genuine pregnancy was preceded by abortions in 19 women, of whom 11 had formal abortions, 3 had criminal abortions, and 5 had spontaneous abortions at 10 to 25 weeks' gestation against a background of chronic pyelonephritis and inflammatory diseases of the uterine appendages.
38
Toufik, Hamza, Mohammed A. Ghassem, Abderrahim Majjad, Aziza Mounach e Ahmed Bezza. "Spondyloarthritis Associated with Uveitis: A Review". Middle East African Journal of Ophthalmology 30, n.º 3 (julho de 2023): 177–81. http://dx.doi.org/10.4103/meajo.meajo_132_21.
Texto completo da fonteResumo:
Spondyloarthritis (SpA) is a group of chronic inflammatory rheumatism characterized by common clinical, radiological, and biological manifestations occurring on a predisposing genetic background dominated by the HLA-B27 antigen. Acute anterior uveitis is the most common extra-articular feature of SpA. The objective of this review is to describe the prevalence, demographic characteristics, factors favoring the occurrence of uveitis in patients with SpA, clinical manifestations, and their therapeutic management.
39
Malik, Altaf Ahmed, Mohd Arif Kelam e Susheel Kumar Sharma. "Prevalence and spectrum of rheumatological diseases in a newly formed Peripheral Medical College in Northern India". International Journal of Research in Medical Sciences 11, n.º 6 (29 de maio de 2023): 2077–81. http://dx.doi.org/10.18203/2320-6012.ijrms20231621.
Texto completo da fonteResumo:
Background: Rheumatic disorders are chronic inflammatory and non-inflammatory disorders of the musculoskeletal system and connective tissue causing a significant socioeconomic burden resulting in immense morbidity owing to poor quality of life, loss of function and productivity. Methods: In this prospective study, consecutive patients attending Medicine Outpatient Department at GMC Doda, between august 2019 and July 2022, were studied for various rheumatological diseases. Rheumatological diagnoses of 3560 consecutive newly detected and returning patients were recorded for three year. Results: During the study period, a total of 27546 patients visited the Medicine OPD, 3560 of which were diagnosed with various rheumatic diseases, yielding a prevalence of 12.9%. The mean age of the patients in the study was 42.33±13.18 years ranging from a minimum age of 18 to a maximum age of 96 years. Females were notably predominant in all diseases at 64%. Non inflammatory rheumatological disorders osteoarthritis and soft tissue rheumatism were most predominant in this study. Conclusions: Osteoarthritis and soft tissue rheumatism were the most predominant rheumatic disorders in our study. Rheumatic diseases constitute a major disease burden in almost all of the age groups, especially in young patients (30-50 years) within our setup.
40
van Eijk-Hustings, Yvonne, Astrid van Tubergen, Carina Boström, Elena Braychenko, Beate Buss, José Felix, Jill Firth et al. "EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis". Annals of the Rheumatic Diseases 71, n.º 1 (28 de outubro de 2011): 13–19. http://dx.doi.org/10.1136/annrheumdis-2011-200185.
Texto completo da fonteResumo:
ObjectivesThe authors aim to develop European League Against Rheumatism recommendations for the role of the nurse in the management of patients with chronic inflammatory arthritis, to identify a research agenda and to determine an educational agenda.MethodsA task force made up of a multidisciplinary expert panel including nurses, rheumatologists, occupational therapist, physiotherapist, psychologist, epidemiologist and patient representatives, representing 14 European countries, carried out the development of the recommendations, following the European League Against Rheumatism standardised operating procedures.The task force met twice. In the first meeting, the aims of the task force were defined, and eight research questions were developed. This was followed by a comprehensive, systematic literature search. In the second meeting, the results from the literature review were presented to the task force that subsequently formulated the recommendations, research agenda and educational agenda.ResultsIn total, 10 recommendations were formulated. Seven recommendations covered the contribution of nurses to care and management: education, satisfaction with care, access to care, disease management, psychosocial support, self-management and efficiency of care. Three recommendations focused on professional support for nurses: availability of guidelines or protocols, access to education and encouragement to undertake extended roles. The strength of the recommendations varied from A to C, dependent on the category of evidence (1A–3), and a high level of agreement was achieved. Additionally, the task force agreed upon 10 topics for future research and an educational agenda.Conclusion10 recommendations for the role of the nurse in the management of chronic inflammatory arthritis were developed using a combination of evidence-based and expert consensus approach.
41
Bouchrane, Ramadhane, Adama Bah, Harine Abdel Aziz Garba, Vanessa Lienou Tagne, Anne Stéphanie Elodie Doun Fouda, Moustapha Niasse e Saïdou Diallo. "Ankylosing Spondylitis and Right Lower Limb Lymphoedema A Rare Association: A Case Report and Review of the Literature". SAS Journal of Medicine 9, n.º 1 (14 de janeiro de 2023): 40–46. http://dx.doi.org/10.36347/sasjm.2023.v09i01.009.
Texto completo da fonteResumo:
Introduction: Ankylosing spondylitis or rheumatic pelvispondylitis is a chronic inflammatory rheumatism characterized by an axial localization predominantly in the spine and sacroiliac joints, an involvement of the entheses and a tendency to bone ankylosis by ossification of these entheses. We report an observation of right lower limb lymphedema associated with ankylosing spondylitis. Observation: This was a 63-year-old patient with a history of inflammatory rheumatism (his older sister) and osteoporosis (his mother), He was diagnosed with ankylosing spondylitis based on enthesis involvement (bilateral tilted gluteal pain and low inflammatory back pain) with a positive HLA-B27 antigen by the 8-point Amor criteria for spondyloarthritis (right unilateral sacroiliitis, low inflammatory back pain, bilateral tilted gluteal pain, HLA-B27+ and NSAID sensitivity). The unilateral lymphedema with positive Stemmer's sign affected the lower 2/3 of the right lower limb. It occurred one year after the onset of ankylosing spondylitis. The echo-Doppler scan showed no signs of thrombosis or venous infiltration of the lower limbs, and diffuse infiltration of the subcutaneous tissue of the right leg without inflammatory character. Treatment of ankylosing spondylitis gradually improved the lymphedema. Conclusion: Lymphedema is a rare complication of ankylosing spondylitis. Dermatologists should be alert to early swelling of the extremities in patients with ankylosing spondylitis so as not to delay specific multidisciplinary treatment and measures to avoid irreversible lymphatic damage.
42
Takhrifa, N., T. Fatima Zahrae, I. Berrichi, A. Anass, K. Berrada e F. Abourazzak. "AB1575-PARE DIETS AND JOINT SYMPTOMS: SURVEY OF MOROCCAN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISM". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 1886.3–1887. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4694.
Texto completo da fonteResumo:
BackgroundThe role of diet in triggering or aggravating chronic diseases, in particular chronic inflammatory rheumatism (CIR), is a question frequently asked by patients.ObjectivesThe objective of our study is to investigate whether Moroccan patients report a relationship between certain diets or foods and the symptoms of the disease and also to study whether patients adopt specific eating behaviors in order to relieve their symptoms.MethodsThis is a survey based on a questionnaire that included any patient followed for CIR who presents to the rheumatology department. The questionnaire has 3 parts: 1) Sociodemographic data, comorbidities, and information on the CIR (type, duration of evolution, activity, functional impact and treatments), 2) beliefs and attitudes of patients in this regarding diet in relation to their CIRs 3) a list of 24 foods for which patients are asked whether they worsen, improve or leave their joint symptoms unchanged.ResultsTo date we have included 120 patients. The average age was 45.3 ± 13.4, 73.3% of the patients were women, 39.3% had comorbidities, 50% were illiterate, 57.5% were followed for RA and 42.5% for SPA. The median duration of evolution of the RIC was 7 years [3; 15], for the treatments 45% of the patients in our study were on corticosteroid therapy, 3.3% used a biological treatement while 7.5% received no treatment.25% of patients think that the diet influences the activity and/or the evolution of the rheumatism. 26% of subjects said food had an effect on their CIR, with 11.7% reporting improvement and 25% worsening. Honey (6.7%), garlic (5%) and olive oil (4.2%) were the foods most often cited as improving CIR symptoms, while red meat (18.3%), fish (6.7%) and legumes (3.3%) were most often cited as aggravating symptoms. 20.8% of patients declare that they have avoidance behaviors vis-à-vis certain foods while 7.5% adopt certain diets and 3.3% have already tried fasting in order to relieve joint symptoms.In uni and multivariate analysis no factor, only the duration of evolution was associated with the fact of declaring that food has an influence on the symptoms of the CIR (OR: 0.947, IC95%: [0.901-0.996], p=0.03).ConclusionThe results of our investigation suggest a possible link between certain foods and joint pain in patients followed for CIR.References[1]Sara K. Tedeschi et al, Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry, 2017 Arthritis Care & ResearchDisclosure of InterestsNone declared
43
Bello, S., R. Fanizzi, C. Rotondo, A. Rinaldi, L. Dinoia, S. Lopriore, L. Serafino, C. Bonali, F. Iannone e G. Lapadula. "AB0448 Drug Survival of A Patients Cohort with Chronic Inflammatory RHEUMATISM Treated with Abatacept". Annals of the Rheumatic Diseases 73, Suppl 2 (junho de 2014): 956.2–956. http://dx.doi.org/10.1136/annrheumdis-2014-eular.2669.
Texto completo da fonte
44
Fayet, Françoise, Angélique Fan, Malory Rodere, Carine Savel, Bruno Pereira e Martin Soubrier. "Adherence to Subcutaneous Anti-TNF Treatment in Chronic Inflammatory Rheumatism and Therapeutic Patient Education". Patient Preference and Adherence Volume 14 (fevereiro de 2020): 363–69. http://dx.doi.org/10.2147/ppa.s240179.
Texto completo da fonte
45
Badra, Kamissoko Aly, Diallo Mamadou Lamine, Traoré Marie, Diallo Alhassane, Yombouno Emmanuel, Barry Abdoulaye, Touré Moriba, Awada Mohamed e Oniankitan Owonayo. "Panorama Des Maladies Rhumatismales A Conakry". European Scientific Journal, ESJ 14, n.º 24 (31 de agosto de 2018): 422. http://dx.doi.org/10.19044/esj.2018.v14n24p422.
Texto completo da fonteResumo:
Objective: To determine the epidemiological profile of rheumatic diseases in hospital consultation at the Ignace Deen National Hospital in Conakry (Guinea). Patients and methods: We used a cross-sectional study of participant seen in rheumatologic consultation between November 1, 2016 and November 30, 2017 at the Rheumatology Department of the Ignace Deen National Hospital in Conakry (Guinea). Rheumatic diseases were diagnosed according to the rigorous criteria. Results: We collected 1038 patients including 679 women (65.41%). The mean age of the patients was 49.88 ± 17.47 years with range of 5 and 93 years. Degenerative pathology (644 cases, 62.04%), chronic inflammatory rheumatism and connective tissue diseases (252 cases, 24.27%), periarticular pathology and canal syndromes (91 cases, 8.76%), microcrystalline arthropathies (49 cases, 4.72%), osteopathies (45 cases, 4.33%), and infectious diseases (16 cases, 1.54%) were the main disorders observed during study period. Conclusion: Most of the rheumatic diseases described in the literature have been found. The particuliarity was the relative frequency of inflammatory rheumatism and fracture osteoporosis. However, the further epidemiological studies would be needed to confirm these data.
46
Danapur, Vijay. "Preliminary Phytochemical and Pharmacognostic Studies on a Well-known Medicinal Plant Glycyrrhiza glabra". International Journal of Pharmacognosy & Chinese Medicine 3, n.º 4 (2019): 1–5. http://dx.doi.org/10.23880/ipcm-16000191.
Texto completo da fonteResumo:
Glycyrrhiza glabra is a perennial herb in the subtropical and warm temperate regions. The principal constituent of licorice is glycyrrhizin. Licorice is used for the treatment of asthma, acute and chronic bronchitis and chronic cough. It modulates the immune system and has remarkable immuno-stimulant properties. The phyto-constituents like glycyrrhizin and glycyrrhizinic acid, triterpenoid glycosides (saponins), flavonoids (including liquiritigetol) are potent components for health benefits. It is a mild anti-inflammatory for arthritis and rheumatism and is used to treat gastric, duodenal and esophageal ulceration of inflammation, heartburn and mouth ulcers. Since it has got so many pharmacological activities it is important to standardize this drug, hence the present study.
47
Akhtar, Most A., Ritesh Raju, Karren D. Beattie, Frances Bodkin e Gerald Münch. "Medicinal Plants of the Australian Aboriginal Dharawal People Exhibiting Anti-Inflammatory Activity". Evidence-Based Complementary and Alternative Medicine 2016 (2016): 1–8. http://dx.doi.org/10.1155/2016/2935403.
Texto completo da fonteResumo:
Chronic inflammation contributes to multiple ageing-related musculoskeletal and neurodegenerative diseases, cardiovascular diseases, asthma, rheumatoid arthritis, and inflammatory bowel disease. More recently, chronic neuroinflammation has been attributed to Parkinson’s and Alzheimer’s disease and autism-spectrum and obsessive-compulsive disorders. To date, pharmacotherapy of inflammatory conditions is based mainly on nonsteroidal anti-inflammatory drugs which in contrast to cytokine-suppressive anti-inflammatory drugs do not influence the production of cytokines such as tumour necrosis factor-α or nitric oxide. However, their prolonged use can cause gastrointestinal toxicity and promote adverse events such as high blood pressure, congestive heart failure, and thrombosis. Hence, there is a critical need to develop novel and safer nonsteroidal anti-inflammatory drugs possessing alternate mechanism of action. In this study, plants used by the Dharawal Aboriginal people in Australia for the treatment of inflammatory conditions, for example, asthma, arthritis, rheumatism, fever, oedema, eye inflammation, and inflammation of bladder and related inflammatory diseases, were evaluated for their anti-inflammatory activity in vitro. Ethanolic extracts from 17 Eucalyptus spp. (Myrtaceae) were assessed for their capacity to inhibit nitric oxide and tumor necrosis factor-α production in RAW 264.7 macrophages. Eucalyptus benthamii showed the most potent nitric oxide inhibitory effect (IC50 5.57±1.4 µg/mL), whilst E. bosistoana, E. botryoides, E. saligna, E. smithii, E. umbra, and E. viminalis exhibited nitric oxide inhibition values between 7.58 and 19.77 µg/mL.
48
Purba, Rentawati, Siti Marlina e Adi Arianto. "PENATALAKSANAAN KOMPRES HANGAT JAHE PADA PENDERITA ARTRITIS REUMATOID DI PUSKESMAS TALUN KENAS". Jurnal Pengabdian Masyarakat Putri Hijau 1, n.º 1 (15 de janeiro de 2021): 19–24. http://dx.doi.org/10.36656/jpmph.v1i1.523.
Texto completo da fonteResumo:
Rheumatism (Rheumatoid Arthritis) is a chronic of systemic inflammatory the disease, systemic inflammation that can be affect tissues and organs, especially attacking flexible (synovial) joints (WHO, 2016). Based on the American of college Rheumathology (2013) states that 52.5 million or approximately 23 % of the population of United States suffer from rheumatoid arthritis. It is estimated that at least 355 million of the world population suffer from rheumatism, which means that 1 in 6 of the world's population of the experiences rheumatic disease. The results of the survey on the European continent in 2004 showed that rheumatic disease was the most common chronic disease. Approximately 50% of Europeans aged over 50 years experience musculoskletal pain complaints (North Sumatra Province Health Service, 2010). All the types of rheumatism cause disruptive pain so that one's of the ability to move can be disrupted by rheumatic disease (Riskesdes, 2007 in Maj. Medicine Indonesia, 2009). One of the non-pharmacological interventions that nurses can do independently in reducing the scale of rheumatoid arthritis pain is by compressing warm ginger (Sentoso, 2013). The design of the reseach used Pre-Experiment using One Grop design. The design of theTest is Pre-Post. The sample of the Reseach was 13 people. the results of the test is t test statistical test the effect of ginger compresses on the decrease in pain scale is known that the value of p = 0.001 is p <0.05 thus Ho is rejected which means there is the effect of ginger warm compresses on the reduction in rheumatoid arthritis pain scale.
49
Ariyanto, Ariyanto, e Tina Yuli Fatmawati. "PENATALAKSANAAN ARTHRITIS RHEUMATOID PADA LANJUT USIA DI PANTI SOSIAL TRESNA WERDHA BUDI LUHUR JAMBI". Jurnal Abdimas Kesehatan (JAK) 1, n.º 2 (28 de junho de 2019): 104. http://dx.doi.org/10.36565/jak.v1i2.33.
Texto completo da fonteResumo:
Rheumatoid arthritis is a chronic systemic inflammatory disease that attacks several joints, the synovium, which occurs in the inflammatory process that causes damage to the joints. The problem faced by partners is that most elderly people still do not understand rheumatism management properly such as a healthy diet, the importance of maintaining body weight to avoid obesity and have not understood traditional rheumatoid management with lemongrass therapy. This community service activity has been conducted at the Tresna Werdha Social Institution in Jambi City in December 2018. The method used a survey, lecture, discussion, demonstration / simulation approach. The results achieved are the implementation of health counseling in the elderly about rheumatoid management, demonstration of lemongrass therapy therapy and conducting pain scale measurements before and after therapy
50
Rodriguez-Morales, Alfonso J., Karol Liceth Hoyos-Guapacha, Sara Lucia Vargas-Zapata, Oscar Mauricio Meneses-Quintero e Julio César Gutiérrez-Segura. "Would be IL-6 a missing link between chronic inflammatory rheumatism and depression after chikungunya infection?" Rheumatology International 37, n.º 7 (26 de maio de 2017): 1149–51. http://dx.doi.org/10.1007/s00296-017-3747-9.
Texto completo da fonte